Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Clinical trial NCT03453619 · COMPLETED
Trial details
- NCT number
- NCT03453619
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-26
- Primary completion
- 2020-04-16
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.